This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Cell & Gene Therapy International Europe
1-3 December 2025
Mercure Hotel MOABerlin, Germany

Karin Hoogendoorn
Head Drug Product Development (CART, Oncology) at Galapagos BV
Speaker

Profile

With over 25 years of experience spanning the pharmaceutical industry from SME to big pharma and academia, Karin has played key roles in CMC-development and CMC- regulatory affairs across the full lifecycle of ATMP development, both in the Netherlands and abroad (Sweden, Switzerland, and Japan). Currently serving as head Drug Product Development CART at Galapagos BV (Leiden, the Netherlands), she brings a wealth of knowledge on CMC, including manufacturing, testing, and comparability strategies for cell and gene therapy products.

Agenda Sessions

  • Panel Discussion: Bringing Cell Therapy to the Patient—Implementing Decentralised Manufacturing

    09:40
  • How to Show Comparability for Fresh (Non-Cryopreserved) Autologous Ex-Vivo Gene Therapy Products, Manufactured across a Network of Decentralised Manufacturing Sites

    11:20